7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for Helicobacter pylori in Taiwan

Abstract EN

Background.

Ten-day concomitant therapy achieves a high eradication rate in Taiwan.

Whether shortening the duration of concomitant therapy can still keep a high eradication rate remains unclear.

Aim.

To assess the eradication rate of 7-day pantoprazole-containing concomitant therapy in Taiwan and to investigate factors influencing the eradication outcome.

Methods.

From March 2008 to March 2012, 319 H.

pylori-infected patients receiving a 7-day pantoprazole-containing concomitant regimen (pantoprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily for 7 days) were included.

Patients were asked to return at the second week to assess drug compliance and adverse effects.

Repeated endoscopy or urea breath test was performed at 8 weeks after the end of eradication therapy.

Results.

The eradication rates according to intention-to-treat and per-protocol analyses were 93.7% (299/319) and 96.4% (297/308), respectively.

Adverse events occurred in 13.2% (42/319) of the patients.

The compliance rate was 98.4% (314/319).

Multivariate analysis disclosed that poor compliance was the only independent factor influencing the efficacy of anti-H.

pylori therapy with an odds ratio of 0.073 (95% confidence interval, 0.011–0.483).

Conclusion.

7-day concomitant therapy achieved a very high eradication rate for H.

pylori infection in Taiwan.

Drug compliance was the only clinical factor influencing treatment efficacy.